The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

Stay up to date on Biogen analyst ratings. Delving into Biogen's Background Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer ...

based biotechnology firm Biogen Idec. In March, Thomas Bucknum, the company's chief counsel, resigned following reports that he had sold stock in the firm just as potential safety problems with the ...

Diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated poliovirus vaccine combined Pediarix (GlaxoSmithKline) 24 hr Manufacturer Diphtheria and ...

Biogen Idec's alpha V beta 6 integrin inhibitor STX-100 and FibroGen's connective tissue growth factor (CTGF) blocker FG-3019. Pharma's interest in fibrosis stems from the realisation that so many ...

The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of ...

Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...